PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Taïeb, Julien
TI  - Results and Subgroup Analyses of the PETACC-8 Trial
DP  - 2012  01
TA  - MD Conference Express
PG  - 9--9
VI  - 12
IP  - 15
4099  - http://mdc.sagepub.com/content/12/15/9.1.short
4100  - http://mdc.sagepub.com/content/12/15/9.1.full
AB  - FOLFOX4 (leucovorin, 5-fluorouracil, and oxaliplatin) has been the standard adjuvant therapy for resected stage III colon cancer since 2004, producing 3-year disease-free survival rates of ∼70%. The aim of the Combination Chemotherapy with or Without Cetuximab in Treating Patients with Stage III Colon Cancer That Was Completely Removed by Surgery [PETACC-8; NCT00265811] trial was to assess the potential benefit of adding cetuximab to standard treatment for colon cancer.